Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can the immune system explain brain and psychiatric symptoms?

NCT ID NCT07791212

Knowledge-focused Sponsor: King's College London Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 27, 2026 · Last updated Aug 28, 2026 · Updated 1 time

Summary

Researchers at King's College London are studying how the immune system relates to neuropsychiatric symptoms, which include mental and neurological issues. They will compare blood and spinal fluid samples from people with such symptoms against samples from healthy controls. The goal is to find immune biomarkers that could improve diagnosis, prognosis, and future treatments. Participants provide blood samples and may give additional samples over a year.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If immune markers are found, they could point toward better diagnosis and new treatments for neuropsychiatric conditions linked to the immune system.
What could go wrong
This is an observational study, so it cannot prove cause and effect. The findings may not apply to everyone, and identifying useful biomarkers is uncertain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 300 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Oct 2026

An estimate. Start dates often move.

Expected to finish

Oct 2036

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Participants with neuropsychiatric symptoms aged 16-100 will be recruited through participating clinical services, while control participants may be recruited through clinical services, research databases, social media, local research networks, and advertisements at collaborating universities and NHS sites.

Ages

16 to 100 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

INCLUSION CRITERIA Participants with Neuropsychiatric symptoms * Age 16-100. * Current or previous neuropsychiatric symptoms within the last year. * Suspicion of immunological contribution to the aetiology of their neuropsychiatric symptoms. Control Participants * Age 16-100. * No current or previous self-report of neuropsychiatric symptoms within the last year. Optional Lumbar Puncture only: \- Documented full blood count within the last 3 months with no clinically significant abnormalities. EXCLUSION CRITERIA All Participants: * Unacceptable risk of harm to participant or study staff due to risk of behavioural disturbance. * Inability to have blood tests. Optional Lumbar Puncture only: * Significant lower spinal deformity (such as spina bifida), injury, or disease (such as stenosis) or previous lower spinal surgery. * Antiplatelet or anticoagulant therapy within the 14 days prior to Lumbar Puncture procedure. * Known or suspected clotting disorder. * Clinically significant abnormality in full blood count. * Known or suspected raised intracranial pressure, assessed by study clinician. * Known or suspected allergy to local anaesthetic agent or an ingredient of the anaesthetic solution. * History of chronic or recurrent headaches, in the opinion of the investigator.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Neuropsychiatric symptom are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

autoimmune disorder of the nervous system catatonia Inflammation Psychotic Disorders

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Neuropsychiatric symptom

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • King's College Hospital

    London, SE5 9RS, United Kingdom

  • South London and Maudsley NHS Foundation Trust

    London, SE5 8AB, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.